|
|||||
![]() |
|
Tobacco company Philip Morris International (NYSE:PM) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 7.1% year on year to $10.14 billion. Its non-GAAP profit of $1.91 per share was 2.8% above analysts’ consensus estimates.
Is now the time to buy PM? Find out in our full research report (it’s free).
Philip Morris' second quarter results for 2025 met non-GAAP earnings expectations but fell short of Wall Street’s revenue consensus, with the market reacting negatively. Management attributed quarterly performance to continued robust growth in smoke-free products, especially IQOS heated tobacco and ZYN nicotine pouches, which together offset challenges in the traditional cigarette business. CFO Emmanuel Babeau highlighted that, “multi-category momentum of our Smoke-Free business accelerated with a Q2 step up in offtake growth for IQOS, ZYN, and VEEV.” The company acknowledged modest declines in cigarette volumes, particularly in Indonesia and Turkey, but emphasized that strong pricing and operational efficiencies supported margins.
Looking forward, Philip Morris’ guidance is anchored by expectations for sustained double-digit volume growth in smoke-free products, ongoing expansion of IQOS and ZYN, and incremental gross margin improvements. Management is focused on scaling new product launches and broadening market access, especially for smoke-free offerings in Europe and the U.S., while closely monitoring headwinds from regulatory developments and illicit trade. Babeau noted, “We expect strong smoke-free momentum to continue...while we factor in the exceptional H2 prior comparison notably on growing combustible volumes, and certain timing factors.” The company plans to leverage increased U.S. production capacity and renewed commercial activity for ZYN to bolster growth in the second half of the year.
Management attributed second quarter results to rapid growth in smoke-free products, resilience in combustibles through pricing, and operational efficiencies, while acknowledging external headwinds in select markets.
Philip Morris’ outlook is shaped by continued smoke-free product growth, expansion in core markets, and ongoing cost discipline, with attention to regulatory and competitive risks.
In the coming quarters, our analysts will watch (1) the pace of smoke-free product adoption, particularly IQOS and ZYN, in both established and new markets; (2) the impact of resumed commercial activity and increased capacity for ZYN in the U.S.; and (3) ongoing regulatory developments, especially EU excise proposals and U.S. FDA authorizations for new products. Margin progression and the company’s ability to manage combustible declines while scaling smoke-free categories will also be key focus areas.
Philip Morris currently trades at $165.85, down from $180.76 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Sep-12 | |
Sep-11 | |
Sep-10 | |
Sep-08 | |
Sep-07 | |
Sep-05 | |
Sep-05 | |
Sep-05 | |
Sep-03 | |
Sep-03 | |
Sep-02 | |
Sep-02 | |
Sep-02 | |
Sep-02 | |
Aug-29 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite